|
1.
|
Börgermann C, Loertzer H, Luboldt HJ, et
al: PSA - Quo vadis? Urologe A. 48:1012–1014. 2009.(In German).
|
|
2.
|
Tannock IF, de Wit R, Berry WR, et al:
Docetaxel plus prednisone or mitoxantrone plus prednisone for
advanced prostate cancer. N Engl J Med. 351:1502–1512. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Centenera MM, Harris JM, Tilley WD and
Butler LM: The contribution of different androgen receptor domains
to receptor dimerization and signaling. Mol Endocrinol.
22:2373–2382. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Knudsen KE and Penning TM: Partners in
crime: deregulation of AR activity and androgen synthesis in
prostate cancer. Trends Endocrinol Metab. 21:315–324. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Wang L, Zou X, Berger AD, et al: Increased
expression of histone deacetylaces (HDACs) and inhibition of
prostate cancer growth and invasion by HDAC inhibitor SAHA. Am J
Transl Res. 1:62–71. 2009.PubMed/NCBI
|
|
6.
|
Weichert W, Röske A, Gekeler V, et al:
Histone deacetylases 1, 2 and 3 are highly expressed in prostate
cancer and HDAC2 expression is associated with shorter PSA relapse
time after radical prostatectomy. Br J Cancer. 98:604–610. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Halkidou K, Gaughan L, Cook S, et al:
Upregulation and nuclear recruitment of HDAC1 in hormone refractory
prostate cancer. Prostate. 59:177–189. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Xu WS, Parmigiani RB and Marks PA: Histone
deacetylase inhibitors: molecular mechanisms of action. Oncogene.
26:5541–5552. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Göttlicher M, Minucci S, Zhu P, et al:
Valproic acid defines a novel class of HDAC inhibitors inducing
differentiation of transformed cells. EMBO J. 20:6969–6978.
2001.PubMed/NCBI
|
|
10.
|
Xia Q, Sung J, Chowdhury W, et al: Chronic
administration of valproic acid inhibits prostate cancer cell
growth in vitro and in vivo. Cancer Res. 66:7237–7244. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Thelen P, Schweyer S, Hemmerlein B, et al:
Expressional changes after histone deacetylase inhibition by
valproic acid in LNCaP human prostate cancer cells. Int J Oncol.
24:25–31. 2004.PubMed/NCBI
|
|
12.
|
Stettner M, Kaulfuss S, Burfeind P, et al:
The relevance of estrogen receptor-beta expression to the
antiproliferative effects observed with histone deacetylase
inhibitors and phytoestrogens in prostate cancer treatment. Mol
Cancer Ther. 6:2626–2633. 2007. View Article : Google Scholar
|
|
13.
|
Yuan R, Kay A, Berg WJ and Lebwohl D:
Targeting tumorigenesis: development and use of mTOR inhibitors in
cancer therapy. J Hematol Oncol. 2:452009. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Li J, Yen C, Liaw D, et al: PTEN, a
putative protein tyrosine phosphatase gene mutated in human brain,
breast, and prostate cancer. Science. 275:1943–1947. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Steck PA, Pershouse MA, Jasser SA, et al:
Identification of a candidate tumour suppressor gene, MMAC1, at
chromosome 10q23.3 that is mutated in multiple advanced cancers.
Nat Genet. 15:356–362. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Jiang BH and Liu LZ: PI3K/PTEN signaling
in angiogenesis and tumorigenesis. Adv Cancer Res. 102:19–65. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Kremer CL, Klein RR, Mendelson J, et al:
Expression of mTOR signaling pathway markers in prostate cancer
progression. Prostate. 66:1203–1212. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Pollak M: Insulin and insulin-like growth
factor signalling in neoplasia. Nat Rev Cancer. 8:915–928. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Han J, Jogie-Brahim S, Harada A and Oh Y:
Insulin-like growth factor-binding protein-3 suppresses tumor
growth via activation of caspase-dependent apoptosis and cross-talk
with NF-κB signaling. Cancer Lett. 307:200–210. 2011.PubMed/NCBI
|
|
20.
|
Franklin SL, Ferry RJ Jr and Cohen P:
Rapid insulin-like growth factor (IGF)-independent effects of IGF
binding protein-3 on endothelial cell survival. J Clin Endocrinol
Metab. 88:900–907. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Igawa T, Lin FF, Lee MS, et al:
Establishment and characterization of androgen-independent human
prostate cancer LNCaP cell model. Prostate. 50:222–235. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
|
|
23.
|
Gerdes J, Lemke H, Baisch H, et al: Cell
cycle analysis of a cell proliferation-associated human nuclear
antigen defined by the monoclonal antibody Ki-67. J Immunol.
133:1710–1715. 1984.PubMed/NCBI
|
|
24.
|
Scholzen T and Gerdes J: The Ki-67
protein: from the known and the unknown. J Cell Physiol.
182:311–322. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Yuan PX, Huang LD, Jiang YM, et al: The
mood stabilizer valproic acid activates mitogen-activated protein
kinases and promotes neurite growth. J Biol Chem. 276:31674–31683.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Blaheta RA and Cinatl J Jr: Anti-tumor
mechanisms of valproate: a novel role for an old drug. Med Res Rev.
22:492–511. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Cheng J, Lee EJ, Madison LD and Lazennec
G: Expression of estrogen receptor β in prostate carcinoma cells
inhibits invasion and proliferation and triggers apoptosis. FEBS
Lett. 566:169–172. 2004.
|
|
28.
|
Horvath LG, Henshall SM, Lee CS, et al:
Frequent loss of estrogen receptor-beta expression in prostate
cancer. Cancer Res. 61:5331–5335. 2001.PubMed/NCBI
|
|
29.
|
Latil A, Bièche I, Vidaud D, et al:
Evaluation of androgen, estrogen (ER alpha and ER beta), and
progesterone receptor expression in human prostate cancer by
real-time quantitative reverse transcription-polymerase chain
reaction assays. Cancer Res. 61:1919–1926. 2001.
|
|
30.
|
Pasquali D, Rossi V, Esposito D, et al:
Loss of estrogen receptor beta expression in malignant human
prostate cells in primary cultures and in prostate cancer tissues.
J Clin Endocrinol Metab. 86:2051–2055. 2001.PubMed/NCBI
|
|
31.
|
Pasquali D, Staibano S, Prezioso D, et al:
Estrogen receptor beta expression in human prostate tissue. Mol
Cell Endocrinol. 178:47–50. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Wedel S, Hudak L, Seibel JM, et al:
Inhibitory effects of the HDAC inhibitor valproic acid on prostate
cancer growth are enhanced by simultaneous application of the mTOR
inhibitor RAD001. Life Sci. 88:418–424. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Chen S, Xu Y, Yuan X, et al: Androgen
receptor phosphorylation and stabilization in prostate cancer by
cyclin-dependent kinase 1. Proc Natl Acad Sci USA. 103:15969–15974.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
34.
|
Azim H, Azim HA Jr and Escudier B:
Targeting mTOR in cancer: renal cell is just a beginning. Target
Oncol. 5:269–280. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35.
|
Zhang W, Zhu J, Efferson CL, et al:
Inhibition of tumor growth progression by antiandrogens and mTOR
inhibitor in a Pten-deficient mouse model of prostate cancer.
Cancer Res. 69:7466–7472. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
36.
|
Fung AS, Wu L and Tannock IF: Concurrent
and sequential administration of chemotherapy and the Mammalian
target of rapamycin inhibitor temsirolimus in human cancer cells
and xenografts. Clin Cancer Res. 15:5389–5395. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
37.
|
Thompson IM Jr, Leach RJ and Ankerst DP:
Prostate cancer detection: a view of the future. Eur Urol.
59:191–193. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
38.
|
Moschos SJ and Mantzoros CS: The role of
the IGF system in cancer: from basic to clinical studies and
clinical applications. Oncology. 63:317–332. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
39.
|
Jogie-Brahim S, Feldman D and Oh Y:
Unraveling insulin-like growth factor binding protein-3 actions in
human disease. Endocr Rev. 30:417–437. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
40.
|
Marelli MM, Moretti RM, Procacci P, et al:
Insulin-like growth factor-I promotes migration in human
androgen-independent prostate cancer cells via the ανβ3 integrin
and PI3-K/Akt signaling. Int J Oncol. 28:723–730. 2006.PubMed/NCBI
|
|
41.
|
Goya M, Miyamoto S, Nagai K, et al: Growth
inhibition of human prostate cancer cells in human adult bone
implanted into nonobese diabetic/severe combined immunodeficient
mice by a ligand-specific antibody to human insulin-like growth
factors. Cancer Res. 64:6252–6258. 2004. View Article : Google Scholar
|
|
42.
|
Wen Y, Hu MC, Makino K, et al: HER-2/neu
promotes androgen-independent survival and growth of prostate
cancer cells through the Akt pathway. Cancer Res. 60:6841–6845.
2000.PubMed/NCBI
|
|
43.
|
Manin M, Baron S, Goossens K, et al:
Androgen receptor expression is regulated by the phosphoinositide
3-kinase/Akt pathway in normal and tumoral epithelial cells.
Biochem J. 366:729–736. 2002.PubMed/NCBI
|
|
44.
|
Rowlands MA, Holly JM, Hamdy F, et al:
Serum insulin-like growth factors and mortality in localised and
advanced clinically detected prostate cancer. Cancer Causes
Control. 23:347–354. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
45.
|
Shabbeer S, Kortenhorst MS, Kachhap S, et
al: Multiple molecular pathways explain the anti-proliferative
effect of valproic acid on prostate cancer cells in vitro and in
vivo. Prostate. 67:1099–1110. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
46.
|
Yagi Y, Fushida S, Harada S, et al:
Effects of valproic acid on the cell cycle and apoptosis through
acetylation of histone and tubulin in a scirrhous gastric cancer
cell line. J Exp Clin Cancer Res. 29:1492010. View Article : Google Scholar : PubMed/NCBI
|
|
47.
|
Machado MC, Bellodi-Privato M, Kubrusly
MS, et al: Valproic acid inhibits human hepatocellular cancer cells
growth in vitro and in vivo. J Exp Ther Oncol. 9:85–92.
2011.PubMed/NCBI
|
|
48.
|
Morgan TM, Pitts TE, Gross TS, et al:
RAD001 (Everolimus) inhibits growth of prostate cancer in the bone
and the inhibitory effects are increased by combination with
docetaxel and zoledronic acid. Prostate. 68:861–871. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
49.
|
Schayowitz A, Sabnis G, Goloubeva O, et
al: Prolonging hormone sensitivity in prostate cancer xenografts
through dual inhibition of AR and mTOR. Br J Cancer. 103:1001–1007.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
50.
|
Corcoran NM, Costello AJ and Hovens CM:
Interfering with cell-survival signalling as a treatment strategy
for prostate cancer. BJU Int. 97:1149–1153. 2006. View Article : Google Scholar : PubMed/NCBI
|
